Little is known about the heterogeneity in low-density lipoprotein cholesterol levels (LDL-C) lowering with proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor medications.
C oncerns have been raised for interindividual variation in the magnitude of low-density lipoprotein cholesterol (LDL-C) level reduction with statin medications and ezetimibe. [1] [2] [3] Inhibition of proprotein convertase subtilisinkexin type 9 (PCSK9) with monoclonal antibodies is an additional approach to lowering LDL-C levels in patients receiving maximally tolerated statin therapy. In the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial (NCT01764633), inhibition of PCSK9 with evolocumab, a fully human monoclonal antibody active against PCSK9, taken with a background of statin therapy reduced LDL-C levels and the risk of cardiovascular events in patients with stable atherosclerotic cardiovascular disease. 4 As with statin medications and ezetimibe, questions about interindividual variability in LDL-C level reduction in response to PCSK9 inhibitors have been raised. Furthermore, many payors require subsequent laboratory testing to demonstrate an optimal LDL-C reduction with PCSK9 inhibitors. The magnitude of individual-level heterogeneity in LDL-C level reduction with evolocumab has not been defined in a largescale trial. Therefore, we examined the interindividual variability in LDL-C level reduction in response to PCSK9 inhibition with evolocumab in the FOURIER trial.
Methods

Study Design and Treatment
The design of the FOURIER trial has been published previously. 4, 5 In brief, FOURIER randomly assigned 27 564 patients with prior myocardial infarction, nonhemorrhagic stroke, or symptomatic peripheral artery disease to receive either evolocumab or placebo. To be eligible, patients were required at the end of the screening period to have an LDL-C level of 70 mg/dL or greater or a non-high-density lipoprotein (HDL) cholesterol of 100 mg/dL or more while taking background lipid-lowering therapies (to convert cholesterol values to millimoles per liter, multiply by 0.0259). Ethics committee approvals for the FOURIER trial were obtained from all relevant organizations locally or through a central institutional review board within the country (including 1242 centers from 49 countries). Each patient provided written informed consent.
At the first 2 or 3 study drug administrations, patients were supervised in the administration of the study drug. After the week 4 visit, patients administered the study drug on their own. Levels of LDL-C were measured on the day of first administration of the study drug and at week 4, week 12, week 24, and every 6 months thereafter.
In the present analysis, we examined the interindividual variation in percentage reduction in LDL-C from baseline with evolocumab and with placebo at 4 weeks and over the course of the first year. Patients with high baseline LDL-C level variability prior to randomization (defined as a >90th percentile [32 mg/dL] difference between final screening phase and randomization LDL-C values) were excluded from the primary analysis (1763 patients in the evolocumab arm and 1761 patients in the placebo arm). Furthermore, patients in the evolocumab and placebo groups who did not receive the study drug, acknowledged an alteration in background lipidlowering therapy, or had missing LDL-C levels at week 4 were excluded (1119 patients in the evolocumab arm and 1153 patients in the placebo arm).
Statistical Analysis
Waterfall plots were used to display the interindividual variation in percent change in LDL-C levels at week 4 in participants using evolocumab and placebo. To generate the placeboadjusted difference, the percentage of LDL-C reduction was rank ordered among patients in each treatment arm, and the value in the placebo arm was subtracted from the corresponding value in the evolocumab arm. Based on the noted criteria, there were 10 902 patients eligible for the analysis in the evolocumab arm and 10 866 in the placebo arm (79% of the number of participants randomized in each arm). To generate exactly equal numbers to permit placebo-adjusted analysis of the rank-ordered results, 36 patients in the evolocumab arm whose values were closest to the median percentage of LDL-C reduction were excluded from the placebo-adjusted analysis. Analyses were done in Stata, version 14.2 (StataCorp). Study data were collected from 2013 to 2016, and data were analyzed in 2018.
Results
A total of 21 768 patients were included in this analysis. The baseline characteristics of the patients in the 2 treatment groups were comparable and are shown in the Table. In the evolocumab group, the median percentage of reduction in LDL-C levels from baseline to week 4 Figure 1A ). Of the 10 902 patients in the evolocumab group, 10 700 (98.1%) demonstrated at least some reduction in LDL-C levels, 10 124 (92.9%) had a reduction of 30% or greater, and 8744 (80.2%) had a reduction of 50% or greater. Among the 2158 patients (19.8%) who did not have at least a 50% reduction in LDL-C level at 4 weeks, 2125 (98.5%) had LDL-C levels measured within the first
Key Points
Question What is the magnitude of interindividual variation in low-density lipoprotein cholesterol level reduction with the proprotein convertase subtilisin kexin 9 inhibitor evolocumab?
Findings In an analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial data, placebo-adjusted analyses show that evolocumab reduced low-density lipoprotein cholesterol levels by 50% or more in 90.5% of patients and by 30% or more in 99.8% of patients.
Meaning
The addition of evolocumab to statin therapy provides a consistent and reliable low-density lipoprotein cholesterol level reduction in most patients.
year, and of those, 1581 (74.4%) had a reduction of 50% or greater. Thus, during the first year in the evolocumab group, 10 325 of 10 902 participants (94.7%) had a reduction of 50% or greater in LDL-C level, 10 669 (97.9%) had a reduction of 30% or greater, and 10 849 patients (99.5%) had at least some reduction in LDL-C levels. Fifty-three patients (0.5%) had no apparent reduction in LDL-C level within the first year.
In the placebo group, the median percentage of reduction in LDL-C level from baseline was 4% (IQR, 13% reduction to 6% increase; baseline median [IQR] Figure 1B ). Despite the exclusion of patients who acknowledged altering their background lipid-lowering therapy use, 531 of 10 866 patients (4.9%) showed an increase of 25% or more in LDL-C levels and 985 of 10 866 patients (9.1%) showed a decrease of 25% or more in LDL-C levels.
In the placebo-adjusted analysis, the median percentage of reduction in LDL-C levels with evolocumab was 61% (IQR, 58%-63%) at 4 weeks ( Figure 2) . Evolocumab reduced the level of LDL-C by 50% or greater in 9839 of 10 866 patients (90.5%) and by 30% or more in 10 846 of 10 866 patients (99.8%), adjusted for changes in the placebo group. This pattern of LDL-C level reduction was consistent across all major subgroups (eTable in the Supplement). A sensitivity analysis that included the 3524 additional patients with high baseline variability in LDL-C levels also showed consistent results with a median percentage of reduction in LDL-C levels of 60% (IQR, 57%-62%) with evolocumab, with 30% or more reduction in 12 601 of 12 627 patients (99.8%).
Discussion
In this secondary analysis of a large randomized clinical trial, the addition of evolocumab to statin therapy lowered LDL-C levels by 50% or greater in more than 90% of patients and by 30% or greater in more than 99% of patients. These findings support the consistency of robust LDL-C level reduction with evolocumab.
The concerns for large interindividual variability in LDL-C level reduction response with PCSK9 inhibitors were first raised in clinical trials with bococizumab, a humanized but not fully human monoclonal antibody targeting PCSK9. 6 In a pooled , waterfall plots showed a large interindividual variation in the LDL-C level reduction with bococizumab, even among patients in whom antidrug antibodies were not detected. 6 In addition, although rare, neutralizing antidrug antibodies have also been noted for alirocumab. 7 Neutralizing antidrug antibodies have not been seen with evolocumab, 4 to our knowledge.
Interindividual variation in LDL-C level reduction with statin use has been observed. 1, 2 These variations have been attributed to demographic, phenotypic, and genetic factors.
8,9
We 10 and others 2 have shown that in patients receiving a highintensity statin only approximately 45% of patients achieve an LDL-C reduction of 50% or greater. In comparison, almost all patients receiving evolocumab achieved a 50% or greater LDL-C level reduction. Because many payors require subsequent laboratory testing to demonstrate an optimal reduction in LDL-C with PCSK9 inhibitors, our findings should reassure clinicians and payors that nearly all patients have a robust LDL-C level reduction and such testing is largely unnecessary. In general practice, nonadherence is likely the most common cause of considerable variation in LDL-C level lowering with a drug. 11, 12 In this study, we excluded patients who a There were no statistically significant differences (P < .05) between the 2 groups for the baseline characteristics described above. acknowledged alteration in background lipid-lowering therapy and those who did not receive or missed the study drug. However, inclusion of patients who did alter background lipidlowering therapy but did not acknowledge it may explain the suboptimal response in LDL-C level reduction observed in a small subset of patients allocated to receive evolocumab. Other potential contributors might include changes in dietary intake, lifestyle modifications, concomitant use of medications that influence lipid metabolism, unappreciated errors in study drug assignment (eg, a wrong kit provided) or administration (eg, improper injection technique), mistakes in laboratory sample labeling or handling, or problems with assays. These factors may also explain the significant changes in LDL-C level (increases or decreases of at least 25%) that were noted in 14% of patients in the placebo arm.
In contrast with what was observed for bococizumab, development of neutralizing antidrug antibodies were not seen in any patient in the FOURIER trial or in follow-up through 5 years in the Open Label Study of Long Term Evaluation Against LDL-C Trial (OSLER) and Open Label Study of Long Term Evaluation Against LDL-C Trial-2 (OSLER-2). 13 However, other theoretical possibilities exist, such as more rapid clearance of evolocumab or diminished efficacy owing to drug target alterations (eg, rare mutations in the LDL receptor). In the present study, only 53 patients (0.5%) in the evolocumab group had no reduction in LDL-C level at any time within the first year. The biological basis of suboptimal response to PCSK9 inhibition in these patients warrants further investigation.
Limitations
Potential limitations should be acknowledged. First, we calculated the placebo-adjusted difference by subtracting the rank-ordered percentage of LDL-C change within the placebo arm from the corresponding value within the evolocumab arm.
Although the baseline characteristics of the 2 groups were comparable, the potential for unmeasured imbalances remains. Second, this analysis was limited to selected population enrolled in a clinical trial; thus, our findings may not be generalizable to the population taking evolocumab. Third, we excluded patients with admitted noncompliance with the study drug but could not exclude patients with unacknowledged noncompliance or unappreciated technical issues in study drug administration. These issues would have no influence on the placebo arm data but potentially a large influence on the evolocumab arm data. The exclusion of patients with noncompliance with the study drug was necessary but does represent a postrandomization variable; however, the baseline characteristics of the patients in the 2 treatment arms used in this analysis remained very similar.
Conclusions
Evolocumab reduced LDL-C levels by 50% or greater in more than 90% of patients and by 30% or greater in more than 99% of patients. These findings provide reassurance that LDL-C level can be robustly reduced with evolocumab without concern for considerable individual-level variability in response. To generate placebo-controlled difference (gray) in the percentage of change in LDL-C, the percentage of change in LDL-C was rank ordered among patients in each treatment group and the value in the placebo group (dark blue) was subtracted from the corresponding value in the evolocumab group (orange). Percent LDL-C change are expressed as median (interquartile change). Race was reported by the patients. Statin intensity was categorized in accordance with the guidelines of the American College of Cardiology and American Heart Association. LDL-C, low-density lipoprotein cholesterol.
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